Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?

Johnson & Johnson (NYSE:JNJ) has secured Chinese approval for Icotyde, its once-daily oral treatment for moderate-to-severe plaque psoriasis. The decision gives the company another route into a market where more than 8.4 million people are affected by psoriasis, according to J&J.

Icotyde could appeal to patients who prefer a pill over an injectable treatment, potentially helping J&J reach new patients and strengthen its existing psoriasis portfolio. However, investors need to monitor when the drug will become available in China, what it will cost, and how much revenue it expects to generate.

Bull Case

Icotyde’s oral formulation is central to its commercial potential, as the global psoriasis market is largely dominated by injectable treatments, including J&J’s Tremfya and AbbVie’s Skyrizi. A once-daily pill may provide an alternative for eligible patients who are reluctant to begin or continue treatment through injections. Wall Street analysts have described Icotyde as having “blockbuster potential,” citing its profile as an oral treatment and its ability to compete for market share currently held by injectable medicines. That remains an analyst assessment rather than a company forecast, but Chinese approval gives J&J access to a potentially substantial patient population.

J&J estimates that psoriasis affects more than 8.4 million people in China. Icotyde is specifically approved for moderate-to-severe plaque psoriasis, so the total figure should not be interpreted as the drug’s eligible market. Nevertheless, the broader prevalence indicates that China carries a considerable burden from the disease. The approval also expands the range of psoriasis treatments available from J&J. Tremfya is already one of the therapies used for the condition, while Icotyde introduces an oral option. Offering different methods of administration could allow the company to address varying patient and physician preferences.

China is the world’s second-largest pharmaceutical market, making the authorization strategically important beyond the immediate sales opportunity. If J&J can secure access and meaningful adoption, Icotyde could become another contributor to its pharmaceutical portfolio in the country.

Bear Case

It is significant to keep in mind that approval alone does not establish how successful the launch will be. When Reuters asked about availability, pricing and local sales expectations, a J&J spokesperson referred to the company’s statement. Investors therefore lack several pieces of information needed to estimate Icotyde’s near-term commercial contribution. The addressable market is also smaller than the headline prevalence figure suggests. More than 8.4 million people may have psoriasis in China, but Icotyde is approved specifically for moderate-to-severe plaque psoriasis, and the current information does not disclose how many Chinese patients fall within that category or are suitable for treatment.

J&J will also face established competition in this domain, as other psoriasis treatments in China include Bristol Myers Squibb’s Sotyktu, AbbVie’s Skyrizi, and J&J’s own Tremfya. Icotyde may win patients from injectable therapies, but it could also shift some demand away from Tremfya rather than generating entirely incremental sales for J&J.

The oral market may become more crowded. China’s Innocare Pharma and Japan’s Takeda Pharmaceutical are developing experimental oral psoriasis treatments. Their products are not described as approved in the supplied information, but successful development could eventually reduce Icotyde’s differentiation as an oral alternative.

Conclusion

Icotyde gives J&J a once-daily oral treatment in a large Chinese psoriasis market and complements its existing Tremfya franchise. Its formulation could help the company reach eligible patients who prefer pills over injections.

The commercial opportunity cannot yet be quantified, however. Pricing, availability, eligible-patient numbers, and expected sales remain undisclosed. While Icotyde’s approval is an important regulatory achievement, its adoption and whether it adds to or partly replaces Tremfya revenue would determine its ultimate value to J&J.

READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth? 

This article is originally published at Insider Monkey.